Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis
Article in Expert Review of Pharmacoeconomics & Outcomes Research (March 2024)
The most recent citing publications are shown below. View all 2 publications that cite this research output on Dimensions.
Research progress of immune checkpoint inhibitors combined with SABR in the treatment of metastatic renal cell carcinoma
Article in International Journal of Urology and Nephrology (January 2023)